J.R.Bruning Talking Risk
J.R.BruningOn democracy, policy & public-interest stewardship of manmade tech
| Platform |  | Pricing | Only free issues | Publishes | Weekly |
|---|---|---|---|---|---|
| Issues | 85 | Subscribers | Read | jrbruning.substack.com |
Curious about how many subscribers J.R.Bruning Talking Risk has or want to find similar newsletters? Reletter has got you covered. We collated all the information we could find from across the web in our database of over one million newsletters.
Check the email archives, get traffic estimates, engagement scores and more to discover the best advertising opportunities.
Our search tool helps you locate relevant newsletters for any topic and compare their stats for better sponsorship decisions.
Latest Issues
Recent posts by this newsletter. Browse the email archive.
Is Facebook protecting Big Pharma?
* Edit. Oct 27, 2024. Not only are you not permitted to post the documentary - you are not permitted to post this Substack talking about the banning of the documentary.
Is an Australian Impact Assessment claiming cost-benefit for the new censorship regime by claiming consensus on risk and efficacy?
The management of information and hence knowledge, concerns as much what is known, as what is not known. Censorship involves ensuring that we don’t know certain types of information exists. Censorship can be obvious, or it can be a little m...
Media omissions fuel division on fluoride?
#### REJECTED BY MSM - ARTICLE ON FLUORIDE RISK TO CHILDREN
FSANZ’S paradigm shift in gene-edited food regulation to excluding a wide range of gene edited foods from being categorised as GMOs.
I’m grateful to The Spectator Australia for publishing this latest piece today. You can get the first month free if you sign up. This is the first article published in mainstream media in Australia or New Zealand discussing the FSANZ propos...
Authors
The writers behind this newsletter.
NZ based sociologist. Primary focus: regulation of manmade tech in the public interest. Relationship between governance, policy & provenance of scientific & technical knowledge. Trustee Physicians & Scientists for Global Responsibility (@PSGRNZ).
Frequently Asked Questions
How can I access the email archive for J.R.Bruning Talking Risk?
You can find recent issues that have been published by J.R.Bruning Talking Risk on Reletter by scrolling up to where it says Latest Issues. Tap on the link for any of the most recent emails or hit More Issues to see older ones.
How many subscribers does J.R.Bruning Talking Risk have?
To see how many people subscribe to J.R.Bruning Talking Risk, simply upgrade your Reletter account. We provide readership numbers and lots of other stats for this newsletter so you can decide if it's worth reaching out to.
How can I advertise in J.R.Bruning Talking Risk?
Newsletter advertising can be extremely effective when it's done right. Before you pitch J.R.Bruning Talking Risk as a potential sponsor or partner, make sure that you've done your research and checked its newsletter stats with Reletter.
Then, personalize one of our winning pitching templates and send it to the right person using the contact info provided.
How much does it cost to sponsor a publication like J.R.Bruning Talking Risk?
Newsletter ad rates (or CPM) vary depending on many factors, including industry, number of subscribers, open rate, ad placement and more.
To find out how much an ad will cost, contact J.R.Bruning Talking Risk using the contact information provided and ask for a copy of their media kit.
How can I find newsletters similar to J.R.Bruning Talking Risk?
Scroll up to where it says Similar Newsletters to see other publications like J.R.Bruning Talking Risk. You can also search our email newsletter directory to discover other newsletters that cover the topics you're interested in.
How do I contact J.R.Bruning Talking Risk?
Reletter provides this newsletter's website URL above, where you will often find their contact information. We also provide links to associated social media accounts and pitching templates so you can reach out fast.